CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6272 result(s)

budesonide (Jorveza )

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: budesonide
Indications: Indicated for the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).

  • Brand Name: Jorveza
  • Manufacturer: AVIR Pharma Inc
  • Project Number: SR0666-000
  • Project Status: Active
  • Submission Type: Initial

voretigene neparvovec (Luxturna)

Last Updated: December 8, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: voretigene neparvovec
Indications: ​Indicated for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

  • Brand Name: Luxturna
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0643-000
  • Project Status: Active
  • Submission Type: Initial

anakinra (Kineret)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: anakinra
Indications: For the treatment of Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.

  • Brand Name: Kineret
  • Manufacturer: Swedish Orphan Biovitrum AB
  • Project Number: SR0662-000
  • Project Status: Active
  • Submission Type: Initial

emicizumab (Hemlibra)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: emicizumab
Indications: Indicated for hemophilia A (congenital factor VIII deficiency) patients with or without factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes. There is limited clinical experience of Hemlibra use in patients with mild or moderate hemophilia A.

  • Brand Name: Hemlibra
  • Manufacturer: Hoffmann-La Roche Ltd.
  • Project Number: ST0651-000
  • Project Status: Active
  • Submission Type: Initial

chlormethine hydrochloride (Ledaga)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: chlormethine hydrochloride
Indications: For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.

  • Brand Name: Ledaga
  • Manufacturer: Recordati Rare Diseases Canada Inc.
  • Project Number: PC0242-000
  • Project Status: Active
  • Submission Type: Initial

Venetoclax (Venclexta)

Last Updated: January 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Venetoclax
Indications: Venclexta is indicated, in combination with a hypomethylating agent or in combination with low-dose cytarabine, in adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

  • Brand Name: Venclexta
  • Manufacturer: AbbVie Corporation
  • Project Number: PC0238-000
  • Project Status: Received
  • Submission Type: Initial